Li Tao, Du Xin, Jia Zhongwei, Zhao Yanlin
Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, China.
Chinese Center for Disease Control and Prevention, Beijing, China.
China CDC Wkly. 2024 Aug 30;6(35):885-890. doi: 10.46234/ccdcw2024.189.
WHAT IS ALREADY KNOWN ABOUT THIS TOPIC?: The recurrence of tuberculosis (TB) following successful treatment presents a significant challenge.
WHAT IS ADDED BY THIS REPORT?: Achieving the global End TB Strategy milestones and targets with the current strategies in China is challenging. However, interventions following recovery to prevent recurrence, in conjunction with preventive treatment for latent TB infection (LTBI), will aid in meeting these objectives.
WHAT ARE THE IMPLICATIONS FOR PUBLIC HEALTH PRACTICE?: Implementing interventions to mitigate recurrence is essential for improving TB control strategies both in China and worldwide. Concurrently, the development of new drugs and vaccines should focus on preventing TB recurrence.
关于该主题已知的信息有哪些？：成功治疗后结核病（TB）的复发带来了重大挑战。
本报告补充了哪些内容？：在中国，采用当前策略实现全球终结结核病战略的里程碑和目标具有挑战性。然而，康复后采取预防复发的干预措施，结合潜伏性结核感染（LTBI）的预防性治疗，将有助于实现这些目标。
对公共卫生实践有何启示？：实施减轻复发的干预措施对于改善中国乃至全球的结核病控制策略至关重要。同时，新药和疫苗的研发应侧重于预防结核病复发。
